Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TARGID

Financiado

Cerrado

Host target identification of anti virulence drugs

While short course chemotherapy for drug-susceptible tuberculosis (TB) remains effective, it is relatively inefficient by modern pharmaceutical standards and universally menaced by the dissemination of multidrug-resistant (MDR), e... ver más

31/12/2015

EPFL

193K€

Presupuesto del proyecto: 193K€

Líder del proyecto

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-12-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

EPFL

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2019-104690RB-I00 DESARROLLO DE TERAPIAS ANTI-VIRULENCIA Y ESTUDIO DE LA ADAPT... 139K€ Cerrado

STriTuVaD In Silico Trial for Tuberculosis Vaccine Development 5M€ Cerrado

Slow growth Deciphering the molecular mechanism s behind the evolution... 185K€ Cerrado

NOSTRESS Unraveling the molecular mechanism of nitrosative stress res... 2M€ Cerrado

ITHEMYC Novel immunotherapies for tuberculosis and other mycobacteri... 5M€ Cerrado

ECOEVODRTB Linking within host and between host evolution of multidrug... 3M€ Cerrado

Líder del proyecto

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 193K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto While short course chemotherapy for drug-susceptible tuberculosis (TB) remains effective, it is relatively inefficient by modern pharmaceutical standards and universally menaced by the dissemination of multidrug-resistant (MDR), extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis (M.tb) and synergy with the HIV/AIDS pandemic. Since one third of the world’s population is latently infected with M.tb, successful anti-TB drugs must be able to eliminate persistent bacilli from the reservoir, which makes TB therapy more challenging. Most of the current antibiotics typically kill M.tb rather than targeting bacterial systems important in the virulence of the bacteria and manipulation of the host-specific biochemical pathways. Whereas normally the host immune system is able to destroy invading bacilli, M.tb developed a wide palette of strategies to avoid bactericidal host responses. The major and most studied virulence mechanism of the tuberculosis pathogen is the ESX-1 system, a type VII secretion system which clearly plays an important role in the pathogenicity and the host-pathogen interaction. The ESX-1 system modulates the host defence through different ways like phagosome maturation arrest, inhibition of TLR signalling in macrophages, macrophage apoptosis induction, and interaction with laminin. The here proposed project forms part of a multidisciplinary anti-virulence drug discovery program focusing on the identification of important host cell signalling pathways that are involved in the pathogenesis, entry and intracellular survival of M.tb. Anti-virulence drugs inhibit bacterial targets that interfere with host cell defence pathways during infection or block host signalling pathways modulated by the bacteria, thus defending the host from the pathogen. This novel strategy of anti-virulence drug discovery is a potential alternative to antibiotics, which may be used in combination therapies to shorten TB treatment and prevent resistance.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores